Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Are the Key Milestones in the Shingrix (Zostavax) Market’s Growth Trajectory From 2025 To 2034?

In recent years, the Shingrix (Zostavax) market size has seen a XX (HCAGR). Its growth is projected to increase from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Factors contributing to this growth during the historic period include growing vaccine acceptance, an escalating demand for educational campaigns, a heightening focus on preventive healthcare, an amplification in patients’ education and advocacy endeavors, and an increase in health insurance coverage for immunization.

There is an expectation for the Shingrix (Zostavax) market to undergo XX (FCAGR) in the coming years, with its size expanding to $XX million in 2029, experiencing a compound annual growth rate (CAGR) of XX%. Growth during the predicted period can be associated with an increase in the aged population, a rise in herpes zoster cases, escalating occurrences of chickenpox, growing disease preponderance, and enhanced consciousness regarding shingles and related complications. The forecast period will encounter significant trends like inventive recombinant vaccines, advancements in developing vaccines, a trend towards disease prevention versus treatment, AI-driven research and development of vaccines, and sophisticated biomarker identification for susceptibility to shingles.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp

What Are the Core Market Drivers Propelling Growth in the Shingrix (Zostavax) Industry?

The escalating uptake of vaccinations is projected to fuel the expansion of the shingrix (zostavax) market. Vaccination involves administering a vaccine to stimulate the body’s defense mechanism to identify and counter specific pathogens. The mounting uptake of vaccination is linked to the heightened cognizance of its efficiency in disease prevention, reduction of disease prevalence, and the advent of secure and easily accessible vaccines. Factors such as public health drives, enhanced healthcare structure, and worldwide vaccination endeavors also play a part in its extensive acceptance. Shingrix (Zostavax) offers significant benefits in vaccination by providing potent protection against shingles and its complications. It is especially advantageous for adults aged above 50, considerably reducing the recurrence risk of shingles and post-herpetic neuralgia. For example, a study published by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical publication, indicated that in May 2024, the shingles vaccinations covered by Medicare Part D surged by 46% in the succeeding year post the initiation of the IRA policy in January 2023. Furthermore, in 2022, as corroborated by the Australian Government Department of Health and Aged Care, an Australian government agency, the Australian government asserted that COVID-19 vaccines were freely accessible to all Australians. By the mid of the year 2022, above 34 million primary vaccinations and booster doses had been distributed, with general practices significantly contributing to the rollout, particularly in rural areas. Consequently, the escalating uptake of vaccinations is steering the expansion of the shingrix (zostavax) market.

How Is the Shingrix (Zostavax) Market Segmented?

The shingrix (zostavax) market covered in this report is segmented –

1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)

2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20264&type=smp

Which Regions Are Driving the Next Phase of the Shingrix (Zostavax) Market Growth?

North America was the largest region in the shingrix (zostavax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Shingrix (Zostavax) Industry?

One primary trend in the shingrix (zostavax) market involves the creation of ground-breaking products such as non-live, recombinant subunit adjuvanted vaccines to improve vaccine effectiveness and address the issue of age-related immune reduction in susceptible groups. A non-live, recombinant subunit adjuvanted vaccine is a formulation that includes specific protein parts of a disease-causing organism combined with an augmenting agent to amplify the immune response. In September 2024, the UK-based biopharmaceutical company GSK plc introduced Shingrix, a shingles vaccine. The Recombinant Zoster Vaccine (RZV) is a non-live vaccine that provides up to 97% protection against shingles and post-herpetic neuralgia. It is intended for adults over 50 and immuno-compromised individuals over 18, and is given via intramuscular injection in two doses. The ZOE-50 study revealed that RZV provides up to 97% effectiveness in adults over 50 for up to three years, with recent evidence showing over 80% effectiveness lasting 6 to 10 years after vaccination.

View the full report here:

https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report

How Is the Shingrix (Zostavax) Market Defined and What Are Its Core Parameters?

Shingrix (Zostavax) refers to a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is used for immunizing adults, particularly those aged 50 and older, to reduce the risk of developing shingles and its complications.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20264

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model